Point-of-Care Diagnostics Market Valuation To Surge At Healthy CAGR Through 2032

Market Overview:

The POCD market is segmented by product, platform, sample, end user, and region. The product segment is further segmented into glucose monitoring kits, infectious diseases testing kits, pregnancy and fertility testing kits, hematology testing kits, cardiometabolic monitoring kits, urinalysis testing kits, cholesterol test strips, drugs abuse testing kits, and others. The platform segment is further segmented into microfluidics, dipstick, immunoassay, molecular diagnostics, and others. The sample segment is further segmented into blood, urine, saliva, and others. The end user segment is further segmented into hospitals and clinics, home care settings, and point of care testing centers.

global point-of-care diagnostics market size is expected to be worth around USD 85.8 million by 2032 from USD 40.9 million in 2022, growing at a CAGR of 7.95% during the forecast period from 2022 to 2032.

The key players in the POCD market include Abbott Laboratories, Becton, Dickinson and Company, Danaher Corporation, F. Hoffmann-La Roche Ltd, Johnson Johnson, bioMérieux SA, Siemens Healthineers, Quidel Corporation, Thermo Fisher Scientific Inc., and Sysmex Corporation. These players are engaged in developing innovative POCD products and technologies to meet the growing demand for these products.

– Please check this report :@https://market.us/report/point-of-care-diagnostics-market/

Recent Developments:

The development of new and innovative POCD products and technologies, such as microfluidic devices, molecular diagnostics, and wearable sensors.
The increasing demand for POCD tests in home care settings, due to the growing preference for patient-centric care and the need to reduce healthcare costs.
The increasing prevalence of chronic diseases, such as diabetes, cancer, and cardiovascular diseases, which require regular monitoring and diagnosis.
The rising incidence of infectious diseases, such as HIV/AIDS, malaria, and tuberculosis, which require rapid and accurate diagnosis.
The increasing focus on preventive healthcare, which is driving the demand for POCD tests for early detection of diseases.
The growing regulatory support for the development and commercialization of POCD products.

Market Key Players:

Hoffmann-La Roche Ltd
Danaher
BD
Qiagen
Abbott
Siemens Healthcare AG
Bio Meraux SA
Zoetis, Inc.
Instrumentation Laboratory
Nova Biomedical
Other Key Players

Regional Analysis:

-North America [United States, Canada, Mexico]
-South America [Brazil, Argentina, Columbia, Chile, Peru]
-Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
-Middle East Africa [GCC, North Africa, South Africa]
-Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]mailto:[email protected]

Market Top Segmentations:

Based on Type

Glucose Testing Kits
Coagulation Testing Kits
Fertility/Pregnancy Testing Kits
Infectious Disease Testing Kits
Haematology Testing Kits
Other Product Types

By End-use

Clinics
Hospitals
Home
Other End-uses

Make an inquiry before picking up this report @https://market.us/report/point-of-care-diagnostics-market/#inquiry

Market Drivers:

Increasing prevalence of chronic diseases: Chronic diseases, such as diabetes, cancer, and cardiovascular diseases, are becoming increasingly prevalent worldwide. These diseases require regular monitoring and diagnosis, which can be done more easily and conveniently with POCD tests.
Rising incidence of infectious diseases: Infectious diseases, such as HIV/AIDS, malaria, and tuberculosis, are still a major problem in many parts of the world. POCD tests can be used to quickly and accurately diagnose these diseases, which can help to improve patient outcomes.
Growing demand for POCD tests in home care settings: There is a growing preference for patient-centric care, and this is driving the demand for POCD tests that can be performed in the home. POCD tests can help patients to manage their chronic diseases more effectively and to get the care they need without having to travel to a doctor's office.
Development of new and innovative POCD technologies: There has been significant innovation in POCD technologies in recent years. New technologies, such as microfluidics and molecular diagnostics, are making it possible to develop POCD tests that are more accurate, reliable, and affordable.
Growing regulatory support for POCD products: Regulatory agencies are increasingly supportive of the development and commercialization of POCD products. This is making it easier for companies to bring new POCD tests to market.